Maryland is currently home to 2668 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
NCT05106387
Recruiting
The main purpose of this study is to continue to see how vonsetamig works in the body and to monitor the outcomes after kidney transplant for participants previously treated in the R5459-RT-1944 study (NCT05092347). No study drug will be given during this study.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/20/2025
Locations: John Hopkins Hospital, Baltimore, Maryland
Conditions: Chronic Kidney Disease (CKD)
Register for Updates
MEASuRE: Metreleptin Effectiveness And Safety Registry
NCT02325674
Recruiting
The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA.
Gender:
ALL
Ages:
All
Trial Updated:
06/20/2025
Locations: Nih/Niddk/Deob, Bethesda, Maryland
Conditions: Generalised Lipodystrophy, Partial Lipodystrophy
Register for Updates
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
NCT06511908
Recruiting
Background: Major depressive disorder (MDD) is a serious mental illness that can put people at risk of self-harm and death. Many drugs are used to treat MDD, but it can take a long time for them to be effective. Researchers want to know if a faster-acting drug, (2R,6R)-hydroxynorketamine (HNK), can better treat the symptoms of MDD. Objective: To test a study drug (HNK) in people with MDD. Eligibility: People aged 18 to 70 years with MDD. They must have had a screening assessment under proto... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/19/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Suicide, Depressive Disorder, Treatment-Resistant, Ketamine, Molecular Mechanisms of Pharmacological Action, Neurotransmitter Agents, Excitatory Amino Acid Agents, Physiological Effects of Drugs, Depressive Disorder, Major, Depressive Disorder, Depression, Mental Disorders, Mood Disorders, Behavioral Symptoms
Register for Updates
Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)
NCT04304820
Recruiting
Background: Severe aplastic anemia (SAA) is a rare and serious blood disorder. It causes the immune system to turn against bone marrow cells. Standard treatment for SSA is a combination of 3 drugs (Cyclosporine \[CsA\], Eltrombopag \[EPAG\], and horse anti-thymocyte globulin \[h-ATG\]). Researchers want to see if starting people at a lower dose of CsA with EPAG before giving them h-ATG is helpful. Objective: To learn if early initiation of oral therapy with CsA and EPAG is safe and effective... Read More
Gender:
ALL
Ages:
Between 3 years and 99 years
Trial Updated:
06/19/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Severe Aplastic Anemia
Register for Updates
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
NCT03973268
Recruiting
Background: Most drugs that treat mood disorders take a long time to work. Ketamine works within hours. A dose can last for a week or more. Certain receptors in the brain might help ketamine work. A drug that blocks these receptors might affect how it works. Objective: To see if the antidepressant response of ketamine is linked to AMPA receptors. Eligibility: Adults ages 18-70 with major depression disorder without psychotic features Design: Participants will be screened under protocol 01... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/19/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Depression, Major Depressive Disorder, Major Depression
Register for Updates
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
NCT06568692
Recruiting
This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with capecitabine (Cap) vs. standard dose of Cap alone in patients with advanced or metastatic breast cancer. The goal of the study is to assess the efficacy and safety of PCS6422 + Cap as a treatment option for patients with advanced or metastatic breast cancer who are not eligible for anthracycline- or taxane-containing therapies, or other available therapies, including PD-1 or PARP i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: University of Maryland Medical Center (UMMC), Baltimore, Maryland
Conditions: Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer
Register for Updates
Accelerated Flap Coverage in Severe Lower Extremity Trauma
NCT06293469
Recruiting
The goal of this randomized controlled trial is to determine if accelerated flap coverage compared to standard flap coverage timing leads to improved infection-related complications in patients with open fractures and/or dislocations below the knee. Eligible patients will be randomized to receive either a flap within a goal of 72 hours of injury or standard of care flap timing for the institution. The primary outcome will be a composite outcome to evaluate clinical status 6 months after randomiz... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: R Adams Cowley Shock Trauma Center, Baltimore, Maryland
Conditions: Open Tibia Fracture, Open Dislocation of Ankle, Extremity Fracture Lower, Extremity Injuries Lower
Register for Updates
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
06/18/2025
Locations: Research Site, Annapolis, Maryland
Conditions: Breast Cancer, Early Breast Cancer
Register for Updates
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
NCT05919511
Recruiting
The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: University of Maryland Medical Center, Baltimore, Maryland
Conditions: cGVHD
Register for Updates
Testing the Impact of Smartphone-based Messaging to Support Young Adult Smoking Cessation
NCT05836103
Recruiting
Clinical practice guidelines for smoking cessation emphasize cognitive behavioral therapy (CBT) to help patients develop coping strategies for urges. Mindfulness or Acceptance and Commitment Therapy (ACT) offer a different approach, which teaches smokers psychological flexibility through accepting negative experiences. While there is evidence for the efficacy of both CBT and Mindfulness/ACT smoking cessation interventions, it is unclear if these approaches are efficacious when implemented in rea... Read More
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
06/18/2025
Locations: Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
Conditions: Tobacco Cigarette Smoking
Register for Updates
SPEARHEAD-3 Pediatric Study
NCT05642455
Recruiting
This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers.
Gender:
ALL
Ages:
Between 2 years and 21 years
Trial Updated:
06/18/2025
Locations: National Institutes of Health, Bethesda, Maryland
Conditions: Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Osteosarcoma, Neuroblastoma (NBL)
Register for Updates
Cardiometabolic Screening Program
NCT05386719
Recruiting
This research study is being done to implement a screening program for prediabetes, diabetes, dyslipidemia and/or hyperlipidemia, and higher risk of cardiovascular disease in breast cancer survivors. This program will also help to direct individuals with risk factors to community and institutional resources for management.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Breast Cancer, Early-stage Breast Cancer
Register for Updates